nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2022-9-4-64-74nodgo-884Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSСтимуляторы гемопоэза в лечении и профилактике реакции «трансплантат против хозяина»Hematopoietic stimulants in the treatment and prevention of graft-versus-host diseasehttps://orcid.org/0000-0003-3244-7774ШиринА. Д.ShirinA. D.

к. м. н., научный сотрудник

лаборатория комбинированной терапии опухолей

115478

Каширское шоссе, 23

Москва

Cand. of Sci. (Med.), Researcher

Laboratory of Combination Therapy of Tumors

115478

23 Kashirskoe Shosse

Moscow

shirin-anton@mail.ruhttps://orcid.org/0000-0002-3560-001XВласенкоР. Я.VlasenkoR. Ya.

к. м. н., старший научный сотрудник

лаборатория клеточного иммунитета

115478

Каширское шоссе, 23

Москва

Cand. of Sci. (Med.), Senior Researcher

Laboratory of Cellular Immunity

115478

23 Kashirskoe Shosse

Moscow

vlasenko2002@bk.ruhttps://orcid.org/0000-0002-4370-6578АнисимоваН. Ю.AnisimovaN. Yu.

д. б. н., ведущий научный сотрудник

лаборатория клеточного иммунитета

115478

Каширское шоссе, 23

119049

Ленинский просп., 4

Москва

Dr. of Sci. (Biol.), Leading Researcher

Laboratory of Cellular Immunity

115478

23 Kashirskoe Shosse

119049

4 Leninsky Prosp.

Moscow

n_anisimova@list.ruhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovK. I.

к. м. н., заместитель директора по научной и образовательной работе

НИИ детской онкологии и гематологии

115478

Каширское шоссе, 23

Москва

Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work

Research Institute of Pediatric Oncology and Hematology

115478

23 Kashirskoe Shosse

Moscow

k.kirgizov@ronc.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

д. м. н., заведующий отделением

НИИ детской онкологии и гематологии

отделение детской онкологии и гематологии (химиотерапия гемобластозов) № 1

115478

Каширское шоссе, 23

Москва

Dr. of Sci. (Med.), Head of the Department

Research Institute of Pediatric Oncology and Hematology

Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1

115478

23 Kashirskoe Shosse

Moscow

timurvaliev@mail.ruhttps://orcid.org/0000-0001-7939-5129СтепанянН. Г.StepanyanN. G.

врач-трансфузиолог

НИИ детской онкологии и гематологии

отделение детской онкологии и гематологии с блоком трансплантации костного мозга

115478

Каширское шоссе, 23

Москва

Transfusiologist

Research Institute of Pediatric Oncology and Hematology

Department of Pediatric Oncology and Hematology with a Bone Marrow Transplant Unit

115478

23 Kashirskoe Shosse

Moscow

nara19922@yandex.ruhttps://orcid.org/0000-0003-1091-1521АлиевТ. З.AlievT. Z.

врач-детский онколог

НИИ детской онкологии и гематологии 

отделение детской онкологии и гематологии с блоком трансплантации костного мозга

115478

Каширское шоссе, 23

Москва

Pediatric Oncologist

Research Institute of Pediatric Oncology and Hematology

Department of Pediatric Oncology and Hematology with a Bone Marrow Transplant Unit

115478

23 Kashirskoe Shosse

Moscow

timaliev118@gmail.comМорозевичГ. Е.MorozevichG. E.

к. б. н., старший научный сотрудник

НИИ биомедицинской химии им. В. Н. Ореховича

лаборатория биосинтеза белков

119435

ул. Погодинская, 10, стр. 8

Москва

ResearcherID: ABD-7858-2020

Cand. of Sci. (Biol.), Senior Researcher

Laboratory of Protein Biosynthesis

119121

Bld. 8, 10 Pogodinskaya St.

Moscow

galina.morozevich@inst.msk.ruОдарюкО. А.OdaryukO. A.

главный врач

119602

Мичуринский просп., 16

Москва

Head

119602

16 Michurinsky Prosp.

Moscow

odoxan@mail.ruФилоненкоД. В.FilonenkoD. V.

к. м. н., старший научный сотрудник

отдел общей онкологии

111123

шоссе Энтузиастов, 86

Москва

Cand. of Sci. (Med.), Senior Researcher

Department of General Oncology

111123

86 Shosse Entuziastov

Moscow

filonenkodima@mail.ruhttps://orcid.org/0000-0002-0727-4050НифантьевН. Э.NifantievN. E.

д. х. н., член-корреспондент РАН, профессор, заведующий лабораторией

лаборатория химии гликоконъюгатов

119991

Ленинский просп., 47

Москва

Dr. of Sci. (Chem.), Associate Member of the Russian Academy of Sciences, Professor, Head of the Laboratory

Laboratory for the Chemistry of Glycoconjugates

119991

Leninsky prospect 47

Moscow

nen@ioc.ac.ruhttps://orcid.org/0000-0002-0773-255XНоврузовК. М.NovruzovK. M.

Керям Мурсали оглы Новрузов, лаборант-исследователь

лаборатория клеточного иммунитета

115478

Каширское шоссе, 23

Москва

Laboratory Assistant-Researcher

Laboratory of Cellular Immunity

115478

23 Kashirskoe Shosse

Moscow

nkeryam@gmail.comhttps://orcid.org/0000-0003-0769-1695ЧикилеваИ. О.ChikilevaI. O.

к. б. н., старший научный сотрудник

лаборатория клеточного иммунитета

115478

Каширское шоссе, 23

Москва

Cand. of Sci. (Biol.), Senior Researcher

Laboratory of Cellular Immunity

115478

23 Kashirskoe Shosse

Moscow

irinatchikileva@mail.ruhttps://orcid.org/0000-0002-0132-167XКиселевскийМ. В.KiselevskiyM. V.

д. м. н., профессор, заведующий лабораторией

лаборатория клеточного иммунитета

115478

Каширское шоссе, 23

119049

Ленинский просп., 4

Москва

115478

23 Kashirskoe Shosse

119049

4 Leninsky Prosp.

Moscow

kisele@inbox.ruФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian FederationФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России; ФГАОУ ВО «Национальный исследовательский технологический университет «МИСИС»РоссияN. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; National University of Science and Technology “MISIS”Russian FederationФГБНУ «Научно-исследовательский институт биомедицинской химии имени В. Н. Ореховича»РоссияV. N. Orekhovich Research Institute of Biomedical ChemistryRussian FederationГБУЗ «Городская поликлиника № 8 Департамента здравоохранения города Москвы»РоссияCity Polyclinic No. 8, Department of Health in MoscowRussian FederationГБУЗ «Московский клинический научный центр имени А. С. Логинова Департамента здравоохранения города Москвы»РоссияMoscow Clinical Scientific Center named after A. S. Loginov, Department of Health in MoscowRussian FederationФГБУН «Институт органической химии имени Н. Д. Зелинского Российской академии наук»РоссияN. D. Zelinsky Institute of Organic Chemistry, Russian Academy of SciencesRussian Federation202202022023946474Copyright © Ширин А.Д., Власенко Р.Я., Анисимова Н.Ю., Киргизов К.И., Валиев Т.Т., Степанян Н.Г., Алиев Т.З., Морозевич Г.Е., Одарюк О.А., Филоненко Д.В., Нифантьев Н.Э., Новрузов К.М., Чикилева И.О., Киселевский М.В., 20232023Ширин А.Д., Власенко Р.Я., Анисимова Н.Ю., Киргизов К.И., Валиев Т.Т., Степанян Н.Г., Алиев Т.З., Морозевич Г.Е., Одарюк О.А., Филоненко Д.В., Нифантьев Н.Э., Новрузов К.М., Чикилева И.О., Киселевский М.В.Shirin A.D., Vlasenko R.Y., Anisimova N.Y., Kirgizov K.I., Valiev T.T., Stepanyan N.G., Aliev T.Z., Morozevich G.E., Odaryuk O.A., Filonenko D.V., Nifantiev N.E., Novruzov K.M., Chikileva I.O., Kiselevskiy M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/884

   Режимы кондиционирования, предшествующие трансплантации гемопоэтических стволовых клеток (ТГСК), часто сопровождаются периодом аплазии, характеризующимся тяжелой нейтропенией, анемией и тромбоцитопенией. Длительная антибактериальная и иммуносупрессивная терапия больных с реакцией «трансплантат против хозяина» (РТПХ) усугубляет депрессию гемопоэза. Для коррекции гематологической дисфункции у данных пациентов используют колониестимулирующие факторы, эритропоэтины и агонисты рецепторов тромбопоэтина. Однако эти препараты обладают побочными эффектами, а их стимулирующее действие, как правило, ограничивается одним из ростков кроветворения. Вместе с тем у больных после ТГСК для профилактики и лечения нарушения гемопоэза на фоне РТПХ необходимо применение препаратов, способствующих восстановлению всех ростков гемопоэза. В качестве перспективных препаратов для этой категории больных могут рассматриваться индукторы Toll- и NOD-подобных рецепторов – стимуляторы экстренного гемопоэза. К таким соединениям относятся бактериальные дериваты и сульфатированные поли(олиго)сахариды, способные стимулировать кроветворение, что позволяет рассматривать их как перспективные стимуляторы гемопоэза для лечения и профилактики нарушений иммунного статуса и кроветворения при РТПХ.

   Conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) are often accompanied by a period of aplasia characterized by severe neutropenia, anemia, and thrombocytopenia. Long-term antibacterial and immunosuppressive therapy in patients with graft-versus-host disease (GVHD) exacerbates hematopoietic depression. Colony-stimulating factors, erythropoietins, and thrombopoietin receptor agonists are used to correct hematological dysfunction in these patients. However, these drugs have side effects, and their stimulating effect, as a rule, is limited to one of the hematopoietic lineages. At the same time, in patients after HSCT, for the prevention and treatment of hematopoietic disorders against the background of GVHD, it is necessary to use drugs that promote the restoration of all hematopoietic cell lines. Inducers of Toll- and NOD-like receptors, stimulators of emergency hematopoiesis, can be considered as promising drugs for this category of patients. These compounds include bacterial derivatives and sulfated poly(oligo)saccharides capable of stimulating hematopoiesis, which allows us to consider them as promising stimulants of hematopoiesis for the treatment and prevention of disorders of the immune status and hematopoiesis in GVHD.

реакция «трансплантат против хозяина»гемопоэзиндукторы Toll-подобных рецепторовэкстренный гемопоэзgraft-versus-host diseasehematopoiesisToll-like receptor inductorsemergency hematopoiesisРабота выполнена при финансовой поддержке Российского фонда фундаментальных исследований (грант РФФИ- комфи: проекты № 17-00-00494, 17-00-00495 и 17-00-00496)This work was supported by the Russian Foundation for Basic Research (RFBR-comfi grant: projects nos. 17-00-00494, 17-00-00495 and 17-00-00496)ReferencesPassweg J. R., Baldomero H., Bader P., Bonini C., Cesaro S., Dreger P., Duarte R. F., Dufour C., Kuball J., Farge-Bancel D., Gennery A., Kröger N., Lanza F., Nagler A., Sureda A., Mohty M. Hematopoietic stem cell transplantation in Europe 2014: More than 40 000 transplants annually. Bone Marrow Transplant. 2016; 51 (6): 786–92. doi: 10.1038/bmt.2016.20.Passweg J. R., Baldomero H., Bader P., Bonini C., Cesaro S., Dreger P., Duarte R. F., Dufour C., Kuball J., Farge-Bancel D., Gennery A., Kröger N., Lanza F., Nagler A., Sureda A., Mohty M. Hematopoietic stem cell transplantation in Europe 2014: More than 40 000 transplants annually. Bone Marrow Transplant. 2016; 51 (6): 786–92. doi: 10.1038/bmt.2016.20.Lee K. H., Lee J. H., Choi S. J. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation–frequency and outcomes. Bone Marrow Transplant. 2004; 33 (7): 729–34. doi: 10.1038/sj.bmt.1704428.Lee K. H., Lee J. H., Choi S. J. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation–frequency and outcomes. Bone Marrow Transplant. 2004; 33 (7): 729–34. doi: 10.1038/sj.bmt.1704428.Lin Y., Hu X., Cheng H. Graft-versus-host disease causes broad suppression of hematopoietic primitive cells and blocks megakaryocyte diff erentiation in a murine model. Biol Blood Marrow Transplant. 2014; 20 (9): 1290–300. doi: 10.1016/j.bbmt.2014.05.009.Lin Y., Hu X., Cheng H. Graft-versus-host disease causes broad suppression of hematopoietic primitive cells and blocks megakaryocyte diff erentiation in a murine model. Biol Blood Marrow Transplant. 2014; 20 (9): 1290–300. doi: 10.1016/j.bbmt.2014.05.009.Kuzmina Z., Eder S., Bohm A. Signifi cantly worse survival of patients with NIH-defi ned chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia. 2011; 26 (4): 746–56. doi: 10.1038/leu.2011.257.Kuzmina Z., Eder S., Bohm A. Signifi cantly worse survival of patients with NIH-defi ned chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia. 2011; 26 (4): 746–56. doi: 10.1038/leu.2011.257.Müskens K. F., Lindemans C. A., Belderbos M. E. Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process? Cells. 2021; 10 (8): 2051. doi: 10.3390/cells10082051.Müskens K. F., Lindemans C. A., Belderbos M. E. Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process? Cells. 2021; 10 (8): 2051. doi: 10.3390/cells10082051.Ferrara J. L., Levine J. E., Reddy P., Holler E. Graft-versus-host disease. Lancet. 2009; 373 (9674): 1550–61. doi: 10.1016/S0140-6736(09)60237-3.Ferrara J. L., Levine J. E., Reddy P., Holler E. Graft-versus-host disease. Lancet. 2009; 373 (9674): 1550–61. doi: 10.1016/S0140-6736(09)60237-3.Danziger-Isakov L., Baillie M. G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant. 2009; 23 (3): 295–304. doi: 10.1111/j.1399-0012.2008.00942.x.Danziger-Isakov L., Baillie M. G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant. 2009; 23 (3): 295–304. doi: 10.1111/j.1399-0012.2008.00942.x.Andersohn F., Konzen C., Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007; 146 (9): 657–65. doi: 10.7326/0003-4819-146-9-200705010-00009.Andersohn F., Konzen C., Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007; 146 (9): 657–65. doi: 10.7326/0003-4819-146-9-200705010-00009.Rizzo J. D., Somerfield M. R., Hagerty K. L., Seidenfeld J., Bohlius J., Bennett C. L., Cella D. F., Djulbegovic B., Goode M. J., Jakubowski A. A., Rarick M. U., Regan D. H., Lichtin A. E. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update. Blood. 2008; 111 (1): 25–41. doi: 10.1182/blood-2007-08-109488.Rizzo J. D., Somerfield M. R., Hagerty K. L., Seidenfeld J., Bohlius J., Bennett C. L., Cella D. F., Djulbegovic B., Goode M. J., Jakubowski A. A., Rarick M. U., Regan D. H., Lichtin A. E. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update. Blood. 2008; 111 (1): 25–41. doi: 10.1182/blood-2007-08-109488.Bokemeyer C., Aapro M. S., Courdi A., Foubert J., Link H., Osterborg A., Repetto L., Soubeyran P. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007; 43 (2): 258–70. doi: 10.1016/j.ejca.2006.10.014.Bokemeyer C., Aapro M. S., Courdi A., Foubert J., Link H., Osterborg A., Repetto L., Soubeyran P. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007; 43 (2): 258–70. doi: 10.1016/j.ejca.2006.10.014.Ivanov V., Faucher C., Mohty M., Bilger K., Ladaique P., Sainty D., Arnoulet C., Chabannon C., Vey N., Camerlo J., Bouabdallah R., Maraninchi D., Bardou V. J., Blaise D. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. Transfusion. 2004; 44 (4): 501–8. doi: 10.1111/j.1537-2995.2004.03317.x.Ivanov V., Faucher C., Mohty M., Bilger K., Ladaique P., Sainty D., Arnoulet C., Chabannon C., Vey N., Camerlo J., Bouabdallah R., Maraninchi D., Bardou V. J., Blaise D. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. Transfusion. 2004; 44 (4): 501–8. doi: 10.1111/j.1537-2995.2004.03317.x.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myelodysplastic Syndromes Version 3.2022 – January 13, 2022. [Electronic resource]: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446 (appeal date 02. 07. 2022).NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myelodysplastic Syndromes Version 3.2022 – January 13, 2022. [Electronic resource]: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446 (appeal date 02. 07. 2022).Beguin Y., Baron F., Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica. 1998; 83 (12): 1076–81. PMID: 9949624.Beguin Y., Baron F., Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica. 1998; 83 (12): 1076–81. PMID: 9949624.Pene R., Appelbaum F. R., Fisher L., Lilleby K., Nemunaitis J., Storb R., Buckner C. D. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant. 1993; 11 (3): 219–22. PMID: 8467286.Pene R., Appelbaum F. R., Fisher L., Lilleby K., Nemunaitis J., Storb R., Buckner C. D. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant. 1993; 11 (3): 219–22. PMID: 8467286.Vannucchi A. M., Bosi A., Ieri A., Guidi S., Saccardi R., Lombardini L., Linari S., Laszlo D., Longo G., Rossi-Ferrini P. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: A randomized trial. Bone Marrow Transplant. 1996; 17 (4): 527–31. PMID: 8722349.Vannucchi A. M., Bosi A., Ieri A., Guidi S., Saccardi R., Lombardini L., Linari S., Laszlo D., Longo G., Rossi-Ferrini P. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: A randomized trial. Bone Marrow Transplant. 1996; 17 (4): 527–31. PMID: 8722349.Baron F., Frere P., Fillet G., Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin Cancer Res. 2003; 9 (15): 5566–72. PMID: 14654537.Baron F., Frere P., Fillet G., Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin Cancer Res. 2003; 9 (15): 5566–72. PMID: 14654537.Beguin Y., Maertens J., De Prijck B., Schots R., Seidel L., Bonnet C., Hafraoui K., Willems E., Vanstraelen G., Servais S., Jaspers A., Fillet G., Baron F. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Am J Hematol. 2013; 88 (12): 990–6. doi: 10.1002/ajh.23552.Beguin Y., Maertens J., De Prijck B., Schots R., Seidel L., Bonnet C., Hafraoui K., Willems E., Vanstraelen G., Servais S., Jaspers A., Fillet G., Baron F. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Am J Hematol. 2013; 88 (12): 990–6. doi: 10.1002/ajh.23552.Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., Zwahlen M., Clarke M., Weingart O., Kluge S., Piper M., Rades D., Steensma D. P., Djulbegovic B., Fey M. F., Ray-Coquard I., Machtay M., Moebus V., Thomas G., Untch M., Schumacher M., Egger M., Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet. 2009; 373 (9674): 1532–42. doi: 10.1016/s0140-6736(09)60502-x.Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., Zwahlen M., Clarke M., Weingart O., Kluge S., Piper M., Rades D., Steensma D. P., Djulbegovic B., Fey M. F., Ray-Coquard I., Machtay M., Moebus V., Thomas G., Untch M., Schumacher M., Egger M., Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet. 2009; 373 (9674): 1532–42. doi: 10.1016/s0140-6736(09)60502-x.Bennett C. L., Silver S. M., Djulbegovic B., Samaras A. T., Blau C. A., Gleason K. J., Barnato S. E., Elverman K. M., Courtney D. M., McKoy J. M., Edwards B. J., Tigue C. C., Raisch D. W., Yarnold P. R., Dorr D. A., Kuzel T. M., Tallman M. S., Trifilio S. M., West D. P., Lai S. Y., Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299 (8): 914–24. doi: 10.1001/jama.299.8.914.Bennett C. L., Silver S. M., Djulbegovic B., Samaras A. T., Blau C. A., Gleason K. J., Barnato S. E., Elverman K. M., Courtney D. M., McKoy J. M., Edwards B. J., Tigue C. C., Raisch D. W., Yarnold P. R., Dorr D. A., Kuzel T. M., Tallman M. S., Trifilio S. M., West D. P., Lai S. Y., Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299 (8): 914–24. doi: 10.1001/jama.299.8.914.Demetri G. D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998; 16 (10): 3412–25. doi: 10.1200/jco.1998.16.10.3412.Demetri G. D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998; 16 (10): 3412–25. doi: 10.1200/jco.1998.16.10.3412.Taher A. T., Musallam K. M., Cappellini M. D. β-Thalassemias. N Engl J Med. 2021; 384 (8): 727–43. doi:10.1056/NEJMra2021838.Taher A. T., Musallam K. M., Cappellini M. D. β-Thalassemias. N Engl J Med. 2021; 384 (8): 727–43. doi:10.1056/NEJMra2021838.Singbart G. Adverse events of erythropoietin in long-term and in acute / short-term treatment. Clin Investig. 1994; 72 (6 Suppl): S36–43. PMID: 7950171.Singbart G. Adverse events of erythropoietin in long-term and in acute / short-term treatment. Clin Investig. 1994; 72 (6 Suppl): S36–43. PMID: 7950171.Снеговой А. В. Практические рекомендации по назначению колониестимулирующих факторов с целью профилактики развития фебрильной нейтропении у онкологических больных / А. В. Снеговой [и др.] // Злокачественные опухоли. – 2015. –4 (S): 342–9. URL: https://rosoncoweb.ru/standarts/RUSSCO/2016/35.pdf.Snegovoy A. V., Kogoniya L. M., Kononenko I. B., Kopp M. V., Koroleva I. A., Larionova V. B. Practical recommendations for the appointment of colony-stimulating factors to prevent the development of febrile neutropenia in cancer patients. Zlokachestvennyye opukholi = Malignant tumors. 2015; 4 (S): 342–9. (In Russ.)Ernst P., Bacigalupo A., Ringdén O., Ruutu T., Kolb H. J., Lawrinson S., Skacel T. A phase 3, randomized, placebo-controlled trial of filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation. Arch Drug Inf. 2008; 1 (3): 89–96. doi: 10.1111/j.1753-5174.2008.00013.x.Ernst P., Bacigalupo A., Ringdén O., Ruutu T., Kolb H. J., Lawrinson S., Skacel T. A phase 3, randomized, placebo-controlled trial of filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation. Arch Drug Inf. 2008; 1 (3): 89–96. doi: 10.1111/j.1753-5174.2008.00013.x.Bishop M. R., Tarantolo S. R., Geller R. B., Lynch J. C., Bierman P. J., Pavletic Z. S., Vose J. M., Kruse S., Dix S. P., Morris M. E., Armitage J. O., Kessinger A. A randomized, double-blind trial of fi lgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000; 96 (1): 80–5. doi: 10.1182/blood.v96.1.80.013k35_80_85.Bishop M. R., Tarantolo S. R., Geller R. B., Lynch J. C., Bierman P. J., Pavletic Z. S., Vose J. M., Kruse S., Dix S. P., Morris M. E., Armitage J. O., Kessinger A. A randomized, double-blind trial of fi lgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000; 96 (1): 80–5. doi: 10.1182/blood.v96.1.80.013k35_80_85.Ringden O. T., Le Blanc K., Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: Uses, misuses, misconceptions, and future applications. Exp Hematol. 2005; 33 (5): 505–12. doi: 10.1016/j.exphem.2005.01.009.Ringden O. T., Le Blanc K., Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: Uses, misuses, misconceptions, and future applications. Exp Hematol. 2005; 33 (5): 505–12. doi: 10.1016/j.exphem.2005.01.009.Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. American Society of Clinical Oncology J Clin Oncol. 1996; 14 (4): 1957–60. doi: 10.1200/jco.1996.14.6.1957.Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. American Society of Clinical Oncology J Clin Oncol. 1996; 14 (4): 1957–60. doi: 10.1200/jco.1996.14.6.1957.Khoury H. J., Loberiza F. R. Jr., Ringdén O., Barrett A. J., Bolwell B. J., Cahn J. Y., Champlin R. E., Gale R. P., Hale G. A., Urbano-Ispizua A., Martino R., McCarthy P. L., Tiberghien P., Verdonck L. F., Horowitz M. M. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006; 107 (4): 1712–6. doi: 10.1182/blood-2005-07-2661.Khoury H. J., Loberiza F. R. Jr., Ringdén O., Barrett A. J., Bolwell B. J., Cahn J. Y., Champlin R. E., Gale R. P., Hale G. A., Urbano-Ispizua A., Martino R., McCarthy P. L., Tiberghien P., Verdonck L. F., Horowitz M. M. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006; 107 (4): 1712–6. doi: 10.1182/blood-2005-07-2661.Ringden O., Labopin M., Gorin N. C. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol. 2004; 22 (3): 416–23. doi: 10.1200/jco.2004.06.102.Ringden O., Labopin M., Gorin N. C. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol. 2004; 22 (3): 416–23. doi: 10.1200/jco.2004.06.102.Morris E. S., MacDonald K. P., Kuns R. D., Morris H. M., Banovic T., Don A. L., Rowe V., Wilson Y. A., Raffelt N. C., Engwerda C. R., Burman A. C., Markey K. A., Godfrey D. I., Smyth M. J., Hill G. R. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation Nat Med. 2009; 15 (4): 436–41. doi: 10.1038/nm.1948.Morris E. S., MacDonald K. P., Kuns R. D., Morris H. M., Banovic T., Don A. L., Rowe V., Wilson Y. A., Raffelt N. C., Engwerda C. R., Burman A. C., Markey K. A., Godfrey D. I., Smyth M. J., Hill G. R. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation Nat Med. 2009; 15 (4): 436–41. doi: 10.1038/nm.1948.Kim S., Baek J., Min H. Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: meta-analysis. Arch Pharm Res. 2012; 35 (11): 2013–20. doi: 10.1007/s12272-012-1119-2.Kim S., Baek J., Min H. Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: meta-analysis. Arch Pharm Res. 2012; 35 (11): 2013–20. doi: 10.1007/s12272-012-1119-2.Ringden O., Hassan Z., Karlsson H., Olsson R., Omazic B., Mattsson J., Remberger M. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation. 2010; 90 (9): 1022–9. doi: 10.1097/TP.0b013e3181f585c7.Ringden O., Hassan Z., Karlsson H., Olsson R., Omazic B., Mattsson J., Remberger M. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation. 2010; 90 (9): 1022–9. doi: 10.1097/TP.0b013e3181f585c7.Büchner T. Hematopoietic growth factors in cancer treatment. Stem Cells. 1994; 12 (3): 241–52. doi: 10.1002/stem.5530120301.Büchner T. Hematopoietic growth factors in cancer treatment. Stem Cells. 1994; 12 (3): 241–52. doi: 10.1002/stem.5530120301.Karagiannidis I., Salataj E., Said Abu Egal E., Beswick E. J. G-CSF in tumors: aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 2021; 142: 155479. doi: 10.1016/j.cyto.2021.155479.Karagiannidis I., Salataj E., Said Abu Egal E., Beswick E. J. G-CSF in tumors: aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 2021; 142: 155479. doi: 10.1016/j.cyto.2021.155479.Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol. 2018; 181 (2): 183–95. doi: 10.1111/bjh.15090.Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol. 2018; 181 (2): 183–95. doi: 10.1111/bjh.15090.Ghanima W., Godeau B., Cines D. B., Bussel J. B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012; 120 (5): 960–9. doi: 10.1182/blood-2011-12-309153.Ghanima W., Godeau B., Cines D. B., Bussel J. B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012; 120 (5): 960–9. doi: 10.1182/blood-2011-12-309153.Will B., Kawahara M., Luciano J. P., Bruns I., Parekh S., Erickson-Miller C. L., Aivado M. A., Verma A., Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009; 114 (18): 3899–908. doi: 10.1182/blood-2009-04-219493.Will B., Kawahara M., Luciano J. P., Bruns I., Parekh S., Erickson-Miller C. L., Aivado M. A., Verma A., Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009; 114 (18): 3899–908. doi: 10.1182/blood-2009-04-219493.Di Buduo C. A., Currao M., Pecci A., Kaplan D. L., Balduini C. L., Balduini A. Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT / ERK-dependent pathway activation. Haematologica. 2016; 101 (12): 1479–88. doi: 10.3324/haematol.2016.146746.Di Buduo C. A., Currao M., Pecci A., Kaplan D. L., Balduini C. L., Balduini A. Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT / ERK-dependent pathway activation. Haematologica. 2016; 101 (12): 1479–88. doi: 10.3324/haematol.2016.146746.Bussel J. B., Buchanan G. R., Nugent D. J. A randomized, double-blind study of romiplostim to determine its safety and effi cacy in children with immune thrombocytopenia. Blood. 2011; 118 (1): 28–36. doi: 10.1182/blood-2010-10-313908.Bussel J. B., Buchanan G. R., Nugent D. J. A randomized, double-blind study of romiplostim to determine its safety and effi cacy in children with immune thrombocytopenia. Blood. 2011; 118 (1): 28–36. doi: 10.1182/blood-2010-10-313908.Wang L., Gao Z., Chen X. P., Zhang H. Y., Yang N., Wang F. Y., Guan L. X., Gu Z. Y., Zhao S. S., Luo L., Wei H. P., Gao C. J. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. Sci Rep. 2016; 6: 39003. doi: 10.1038/srep39003.Wang L., Gao Z., Chen X. P., Zhang H. Y., Yang N., Wang F. Y., Guan L. X., Gu Z. Y., Zhao S. S., Luo L., Wei H. P., Gao C. J. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. Sci Rep. 2016; 6: 39003. doi: 10.1038/srep39003.Kuzmina Z., Eder S., Böhm A., Pernicka E., Vormittag L., Kalhs P., Petkov V., Stary G., Nepp J., Knobler R., Just U., Krenn K., Worel N., Greinix H. T. Signifi cantly worse survival of patients with NIH-defi ned chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia. 2012; 26 (4): 746–56. doi: 10.1038/leu.2011.257.Kuzmina Z., Eder S., Böhm A., Pernicka E., Vormittag L., Kalhs P., Petkov V., Stary G., Nepp J., Knobler R., Just U., Krenn K., Worel N., Greinix H. T. Signifi cantly worse survival of patients with NIH-defi ned chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia. 2012; 26 (4): 746–56. doi: 10.1038/leu.2011.257.Kim D. H., Sohn S. K., Baek J. H., Kim J. G., Lee N. Y., Won D. I., Suh J. S., Lee K. B. Clinical signifi cance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation. J Korean Med Sci. 2006; 21 (1): 46–51. doi: 10.3346/jkms.2006.21.1.46.Kim D. H., Sohn S. K., Baek J. H., Kim J. G., Lee N. Y., Won D. I., Suh J. S., Lee K. B. Clinical signifi cance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation. J Korean Med Sci. 2006; 21 (1): 46–51. doi: 10.3346/jkms.2006.21.1.46.Diedrich B., Remberger M., Shanwell A., Svahn B. M., Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 109 per L versus 30 × 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion. 2005; 459 (7): 1064–72. doi: 10.1111/j.1537-2995.2005.04157.x.Diedrich B., Remberger M., Shanwell A., Svahn B. M., Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 109 per L versus 30 × 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion. 2005; 459 (7): 1064–72. doi: 10.1111/j.1537-2995.2005.04157.x.Liu X., Wu M., Peng Y., Chen X., Sun J., Huang F., Fan Z., Zhou H., Wu X., Yu G., Zhang X., Li Y., Xiao Y., Song C., Xiang A. P., Liu Q. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: A pilot prospective study. Cell Transplant. 2014; 23 (9): 1087–98. doi: 10.3727/096368912X661319.Liu X., Wu M., Peng Y., Chen X., Sun J., Huang F., Fan Z., Zhou H., Wu X., Yu G., Zhang X., Li Y., Xiao Y., Song C., Xiang A. P., Liu Q. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: A pilot prospective study. Cell Transplant. 2014; 23 (9): 1087–98. doi: 10.3727/096368912X661319.Ahmed S., Bashir Q., Bassett R., Poon M. C., Valdez B., Konoplev S., Alousi A. M., Andersson B. S., Ciurea S., Hosing C., Jones R., Kebriaei P., Khouri I., Kim S., Nieto Y., Olson A., Oran B., Parmar S., Qazilbash M. H., Rezvani K., Shah N., Shpall E. J., Champlin R., Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021; 27 (5): 430.e1–430.e7. doi: 10.1016/j.jtct.2021.02.004.Ahmed S., Bashir Q., Bassett R., Poon M. C., Valdez B., Konoplev S., Alousi A. M., Andersson B. S., Ciurea S., Hosing C., Jones R., Kebriaei P., Khouri I., Kim S., Nieto Y., Olson A., Oran B., Parmar S., Qazilbash M. H., Rezvani K., Shah N., Shpall E. J., Champlin R., Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021; 27 (5): 430.e1–430.e7. doi: 10.1016/j.jtct.2021.02.004.Kim T. O., Despotovic J., Lambert M. P. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018; 2 (4): 454–61. doi: 10.1182/bloodadvances.2017010660.Kim T. O., Despotovic J., Lambert M. P. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018; 2 (4): 454–61. doi: 10.1182/bloodadvances.2017010660.Gonzalez-Porras J. R., Bastida J. M. Eltrombopag in immune thrombocytopenia: Efficacy review and update on drug safety. Ther Adv Drug Saf. 2018; 9 (6): 263–85. doi: 10.1177/2042098618769587.Gonzalez-Porras J. R., Bastida J. M. Eltrombopag in immune thrombocytopenia: Efficacy review and update on drug safety. Ther Adv Drug Saf. 2018; 9 (6): 263–85. doi: 10.1177/2042098618769587.McHutchison J. G., Dusheiko G., Shiffman M. L., Rodriguez-Torres M., Sigal S., Bourliere M., Berg T., Gordon S. C., Campbell F. M., Theodore D., Blackman N., Jenkins J., Afdhal N. H. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357 (22): 2227–36. doi: 10.1056/NEJMoa073255.McHutchison J. G., Dusheiko G., Shiffman M. L., Rodriguez-Torres M., Sigal S., Bourliere M., Berg T., Gordon S. C., Campbell F. M., Theodore D., Blackman N., Jenkins J., Afdhal N. H. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357 (22): 2227–36. doi: 10.1056/NEJMoa073255.Marsh J. C. W., Mufti G. J. Eltrombopag: A stem cell cookie? Blood. 2014; 123 (12): 1774–5. doi: 10.1182/blood-2014-02-553404.Marsh J. C. W., Mufti G. J. Eltrombopag: A stem cell cookie? Blood. 2014; 123 (12): 1774–5. doi: 10.1182/blood-2014-02-553404.Erickson-Miller C. L., Delorme E., Tian S. S., Hopson C. B., Landis A. J., Valoret E. I., Sellers T. S., Rosen J., Miller S. G., Luengo J. I., Duffy K. J., Jenkins J. M. Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells. 2009; 27 (2): 424–30. doi: 10.1634/stemcells.2008-0366.Erickson-Miller C. L., Delorme E., Tian S. S., Hopson C. B., Landis A. J., Valoret E. I., Sellers T. S., Rosen J., Miller S. G., Luengo J. I., Duffy K. J., Jenkins J. M. Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells. 2009; 27 (2): 424–30. doi: 10.1634/stemcells.2008-0366.Alvarado L. J., Huntsman H. D., Cheng H., Townsley D. M., Winkler T., Feng X., Dunbar C. E., Young N. S., Larochelle A. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFNγ. Blood. 2019; 133 (19): 2043–55. doi: 10.1182/blood-2018-11-884486.Alvarado L. J., Huntsman H. D., Cheng H., Townsley D. M., Winkler T., Feng X., Dunbar C. E., Young N. S., Larochelle A. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFNγ. Blood. 2019; 133 (19): 2043–55. doi: 10.1182/blood-2018-11-884486.Yaman Y., Elli M., Şahin Ş., Özdilli K., Bilgen H., Bayram N., Nepesov S., Anak S. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatr Transplant. 2021; 25 (5): e13962. doi: 10.1111/petr.13962.Yaman Y., Elli M., Şahin Ş., Özdilli K., Bilgen H., Bayram N., Nepesov S., Anak S. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatr Transplant. 2021; 25 (5): e13962. doi: 10.1111/petr.13962.Fu H., Zhang X., Han T., Mo X., Wang Y., Chen H., Han W., Wang J., Wang F., Yan C., Zhang Y., Sun Y., Liu K., Huang X., Xu L. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019; 54 (8): 1310–8. doi: 10.1038/s41409-019-0435-2.Fu H., Zhang X., Han T., Mo X., Wang Y., Chen H., Han W., Wang J., Wang F., Yan C., Zhang Y., Sun Y., Liu K., Huang X., Xu L. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019; 54 (8): 1310–8. doi: 10.1038/s41409-019-0435-2.Bento L., Bastida J. M., García-Cadenas I., García-Torres E., Rivera D., Bosch-Vilaseca A., De Miguel C., Martínez-Muñoz M. E., Fernández-Avilés F., Roldán E., Chinea A., Yáñez L., Zudaire T., Vaz C. P., Espigado I., López J., Valcárcel D., Duarte R., Cabrera R., Herrera C., González-Porras J. R., Gutiérrez A., Solano C., Sampol A. Grupo Español de Trasplante Hematopoyético (GETH). Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019; 25 (9): 1825–31. doi: 10.1016/j.bbmt.2019.05.023.Bento L., Bastida J. M., García-Cadenas I., García-Torres E., Rivera D., Bosch-Vilaseca A., De Miguel C., Martínez-Muñoz M. E., Fernández-Avilés F., Roldán E., Chinea A., Yáñez L., Zudaire T., Vaz C. P., Espigado I., López J., Valcárcel D., Duarte R., Cabrera R., Herrera C., González-Porras J. R., Gutiérrez A., Solano C., Sampol A. Grupo Español de Trasplante Hematopoyético (GETH). Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019; 25 (9): 1825–31. doi: 10.1016/j.bbmt.2019.05.023.Mittelman M., Platzbecker U., Afanasyev B., Grosicki S., Wong R. S. M., Anagnostopoulos A., Brenner B., Denzlinger C., Rossi G., Nagler A., Garcia-Delgado R., Portella M. S. O., Zhu Z., Selleslag D. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): A randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018; 5 (1): e34–e43. doi: 10.1016/S2352-3026(17)30228-4.Mittelman M., Platzbecker U., Afanasyev B., Grosicki S., Wong R. S. M., Anagnostopoulos A., Brenner B., Denzlinger C., Rossi G., Nagler A., Garcia-Delgado R., Portella M. S. O., Zhu Z., Selleslag D. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): A randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018; 5 (1): e34–e43. doi: 10.1016/S2352-3026(17)30228-4.Christakopoulos G. E., DeFor T. E., Hage S., Wagner J. E., Linden M. A., Brunstein C., Bejanyan N., Verneris M. R., Smith A. R. Phase I dose-finding, safety and tolerability trial of Romiplostim to Improve Platelet Recovery after UCB Transplantation. Transplant Cell Ther. 2021; 27 (6): 497.e1–497.e6. doi: 10.1016/j.jtct.2021.02.033.Christakopoulos G. E., DeFor T. E., Hage S., Wagner J. E., Linden M. A., Brunstein C., Bejanyan N., Verneris M. R., Smith A. R. Phase I dose-finding, safety and tolerability trial of Romiplostim to Improve Platelet Recovery after UCB Transplantation. Transplant Cell Ther. 2021; 27 (6): 497.e1–497.e6. doi: 10.1016/j.jtct.2021.02.033.Calmettes C., Vigouroux S., Tabrizi R., Milpied N. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011; 46 (12): 1587–9. doi: 10.1038/bmt.2011.179.Calmettes C., Vigouroux S., Tabrizi R., Milpied N. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011; 46 (12): 1587–9. doi: 10.1038/bmt.2011.179.Battipaglia G., Ruggeri A., Brissot E., Mamez A. C., Malard F., Belhocine R., Vekhoff A., Giannotti F., Ledraa T., Labopin M., Rubio M. T., Mohty M. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015; 50 (12): 1574–7. doi: 10.1038/bmt.2015.182.Battipaglia G., Ruggeri A., Brissot E., Mamez A. C., Malard F., Belhocine R., Vekhoff A., Giannotti F., Ledraa T., Labopin M., Rubio M. T., Mohty M. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015; 50 (12): 1574–7. doi: 10.1038/bmt.2015.182.Maximova N., Zanon D., Rovere F., Maestro A., Schillani G., Paparazzo R. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. Int J Hematol. 2015; 102 (5): 626–32. doi: 10.1007/s12185-015-1821-1.Maximova N., Zanon D., Rovere F., Maestro A., Schillani G., Paparazzo R. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. Int J Hematol. 2015; 102 (5): 626–32. doi: 10.1007/s12185-015-1821-1.Hartranft M. E., Clemmons A. B., Deremer D. L., Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. J Oncol Pharm Pract. 2017; 23 (1): 10–7. doi: 10.1177/1078155215612240.Hartranft M. E., Clemmons A. B., Deremer D. L., Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. J Oncol Pharm Pract. 2017; 23 (1): 10–7. doi: 10.1177/1078155215612240.Kantarjian H., Fenaux P., Sekeres M. A. Becker P. S., Boruchov A., Bowen D., Hellstrom-Lindberg E., Larson R. A., Lyons R. M., Muus P., Shammo J., Siegel R., Hu K., Franklin J., Berger D. P. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010; 28 (3): 437–44. doi: 10.1200/JCO.2009.24.7999.Kantarjian H., Fenaux P., Sekeres M. A. Becker P. S., Boruchov A., Bowen D., Hellstrom-Lindberg E., Larson R. A., Lyons R. M., Muus P., Shammo J., Siegel R., Hu K., Franklin J., Berger D. P. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010; 28 (3): 437–44. doi: 10.1200/JCO.2009.24.7999.Sekeres M. A., Kantarjian H., Fenaux P., Becker P., Boruchov A., Guerci-Bresler A., Hu K., Franklin J., Wang Y. M., Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011; 117 (5): 992–1000. doi: 10.1002/cncr.25545.Sekeres M. A., Kantarjian H., Fenaux P., Becker P., Boruchov A., Guerci-Bresler A., Hu K., Franklin J., Wang Y. M., Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011; 117 (5): 992–1000. doi: 10.1002/cncr.25545.Grainger J. D., Locatelli F., Chotsampancharoen T. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015; 386 (10004): 1649–58. doi: 10.1016/s0140-6736(15)61107-2.Grainger J. D., Locatelli F., Chotsampancharoen T. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015; 386 (10004): 1649–58. doi: 10.1016/s0140-6736(15)61107-2.Cuker A., Chiang E. Y., Cines D. B. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf. 2010; 5 (2): 171–81. URL: https://pubmed.ncbi.nlm.nih.gov/19534637/.Cuker A., Chiang E. Y., Cines D. B. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf. 2010; 5 (2): 171–81. URL: https://pubmed.ncbi.nlm.nih.gov/19534637/.Bento L., Canaro M., Bastida J. M., Sampol A. Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Med. 2022; 11 (5): 1364. doi: 10.3390/jcm11051364.Bento L., Canaro M., Bastida J. M., Sampol A. Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Med. 2022; 11 (5): 1364. doi: 10.3390/jcm11051364.Luo S. S., Ogata K., Yokose N., Kato T. Dan K. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells. 2000; 18 (2): 112–9. doi: 10.1634/stemcells.18-2-112.Luo S. S., Ogata K., Yokose N., Kato T. Dan K. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells. 2000; 18 (2): 112–9. doi: 10.1634/stemcells.18-2-112.Hashimoto S., Toba K., Fuse I. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur J Haematol. 2000; 64 (4): 225–30. doi: 10.1034/j.1600-0609.2000.90001.x.Hashimoto S., Toba K., Fuse I. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur J Haematol. 2000; 64 (4): 225–30. doi: 10.1034/j.1600-0609.2000.90001.x.O’Driscoll D. N. Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic. Ir J Med Sci. 2022; 16: 1–2. doi: 10.1007/s11845-022-03068-w.O’Driscoll D. N. Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic. Ir J Med Sci. 2022; 16: 1–2. doi: 10.1007/s11845-022-03068-w.Mitroulis I., Kalafati L., Hajishengallis G., Chavakis T. Myelopoiesis in the Context of Innate Immunity. J Innate Immun. 2018; 10 (5–6): 365–72. doi: 10.1159/000489406.Mitroulis I., Kalafati L., Hajishengallis G., Chavakis T. Myelopoiesis in the Context of Innate Immunity. J Innate Immun. 2018; 10 (5–6): 365–72. doi: 10.1159/000489406.Trumpp A., Essers M., Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010; 10 (3): 201–9. doi: 10.1038/nri2726.Trumpp A., Essers M., Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010; 10 (3): 201–9. doi: 10.1038/nri2726.Kuderer N. M., Dale D. C., Crawford J., Cosler L. E., Lyman G. H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106 (10): 2258–66. doi: 10.1002/cncr.21847.Kuderer N. M., Dale D. C., Crawford J., Cosler L. E., Lyman G. H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106 (10): 2258–66. doi: 10.1002/cncr.21847.Hérault A., Binnewies M., Leong S., Calero-Nieto F. J., Zhang S. Y., Kang Y. A., Wang X., Pietras E. M., Chu S. H., Barry-Holson K., Armstrong S., Göttgens B., Passegué E. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017; 544 (7648): 53–8. doi: 10.1038/nature21693.Hérault A., Binnewies M., Leong S., Calero-Nieto F. J., Zhang S. Y., Kang Y. A., Wang X., Pietras E. M., Chu S. H., Barry-Holson K., Armstrong S., Göttgens B., Passegué E. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017; 544 (7648): 53–8. doi: 10.1038/nature21693.Nagai Y., Garrett K. P., Ohta S., Bahrun U., Kouro T., Akira S., Takatsu K., Kincade P. W. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006; 24 (6): 801–12. doi: 10.1016/j.immuni.2006.04.008.Nagai Y., Garrett K. P., Ohta S., Bahrun U., Kouro T., Akira S., Takatsu K., Kincade P. W. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006; 24 (6): 801–12. doi: 10.1016/j.immuni.2006.04.008.Boettcher S., Ziegler P., Schmid M. A., Takizawa H., van Rooijen N., Kopf M., Heikenwalder M., Manz M. G. Cutting Edge: LPS-Induced Emergency Myelopoiesis Depends on TLR4-Expressing Nonhematopoietic Cells. J Immunol. 2012; 188 (12): 5824–8. doi: 10.4049/jimmunol.1103253.Boettcher S., Ziegler P., Schmid M. A., Takizawa H., van Rooijen N., Kopf M., Heikenwalder M., Manz M. G. Cutting Edge: LPS-Induced Emergency Myelopoiesis Depends on TLR4-Expressing Nonhematopoietic Cells. J Immunol. 2012; 188 (12): 5824–8. doi: 10.4049/jimmunol.1103253.Калюжин О. В. Мурамилпептиды в эксперименте и клинике / О. В. Калюжин // Журнал микробиологии эпидемиологии и иммунобиологии. – 1998. – 1: 104–8.Kalyuzhin O. V. Muramylpeptides in experiment and clinic. Zhurnal mikrobiologii epidemiologii i immunobiologii = Journal of Microbiology Epidemiology and Immunobiology. 1998; 1: 104–8. (In Russ.)Львов В. Л. Применение композиции, состоящей из низкомолекулярных фрагментов пептидогликана грамотрицательных бактерий, для лечения и профилактики заболеваний человека / В. Л. Львов [и др.] // Патент РФ. – RU2441906C2. – 2012.Lvov V. L., Pinegin B. V., Khaitov R. M., Pashchenkov M. V. The use of a composition consisting of low molecular weight fragments of peptidoglycan of gram-negative bacteria for the treatment and prevention of human diseases. RF patent. RU2441906C2, 2012. (In Russ.)Маркова Т. П. Мурамилпептиды: механизмы действия, клиническая эффективность и перспективы применения в медицине / Т. П. Маркова [и др.] // РМЖ. Медицинское обозрение. – 2020. – 4 (1): 31–7. doi: 10.32364/2587-6821-2020-4-1-31-37.Markova T. P., Chuvirov D. G., Yarilina L. G., Kozhinova E. V. Muramylpeptides: mechanisms of action, clinical effi cacy and prospects for use in medicine. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian medical journal. Medical review. 2020; 4 (1): 31–7. (In Russ.)Ustyuzhanina N. E., Anisimova N. Y., Bilan M. I., Donenko F. V., Morozevich G. E., Yashunskiy D. V., Usov A. I., Siminyan N. G., Kirgisov K. I., Varfolomeeva S. R., Kiselevskiy M. V., Nifantiev N. E. Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice. Pharmaceuticals (Basel). 2021; 14 (11): 1074. doi: 10.3390/ph14111074.Ustyuzhanina N. E., Anisimova N. Y., Bilan M. I., Donenko F. V., Morozevich G. E., Yashunskiy D. V., Usov A. I., Siminyan N. G., Kirgisov K. I., Varfolomeeva S. R., Kiselevskiy M. V., Nifantiev N. E. Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice. Pharmaceuticals (Basel). 2021; 14 (11): 1074. doi: 10.3390/ph14111074Киселевский М. В. Комбинация мурамилпептидов грамотрицательных бактерий корригирует нарушения гемопоэза и клеточного состава селезенки, вызванные циклофосфамидом, у мышей с меланомой B16 / М. В. Киселевский [и др.] // Бюллетень экспериментальной биологии и медицины. – 2020. –170 (12): 772–7. doi: 10.47056/0365-9615-2020-170-12-772-777.Kiselevsky M. V., Anisimova N. Yu., Sitdikova S. M., Donenko F. V., Lvov V. L., Kalyuzhin O. V., Nurtazina A. Yu., Karaulov A. V. A combination of muramyl peptides from gram-negative bacteria corrects cyclophosphamide-induced hematopoiesis and splenic cell composition disorders in mice with B16 melanoma. Byulleten’ eksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2020; 170 (12): 772–7. (In Russ.)Hsu H. Y., Lin T. Y., Lu M. K., Leng P. J., Tsao S. M., Wu Y. C. Fucoidan induces Toll-like receptor 4-regulated reactive oxygen species and promotes endoplasmic reticulum stress-mediated apoptosis in lung cancer. Sci Rep. 2017; 7: 44990. doi: 10.1038/srep44990.Hsu H. Y., Lin T. Y., Lu M. K., Leng P. J., Tsao S. M., Wu Y. C. Fucoidan induces Toll-like receptor 4-regulated reactive oxygen species and promotes endoplasmic reticulum stress-mediated apoptosis in lung cancer. Sci Rep. 2017; 7: 44990. doi: 10.1038/srep44990.Frenette P. S., Weiss L. Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: Evidence for selectin-dependent and independent mechanisms. Blood. 2000; 96 (7): 2460–8. doi: 10.1182/blood.v96.7.2460.h8002460_2460_2468.Frenette P. S., Weiss L. Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: Evidence for selectin-dependent and independent mechanisms. Blood. 2000; 96 (7): 2460–8. doi: 10.1182/blood.v96.7.2460.h8002460_2460_2468.Kubonishi S., Kikuchi T., Yamaguchi S., Tamamura H., Fujii N., Watanabe T., Arenzana-Seisdedos F., Ikeda K., Matsui T., Tanimoto M., Katayama Y. Rapid hematopoietic progenitor mobilization by sulfated colominic acid. Biochem Biophys Res Commun. 2007; 355 (4): 970–5. doi: 10.1016/j.bbrc.2007.02.069.Kubonishi S., Kikuchi T., Yamaguchi S., Tamamura H., Fujii N., Watanabe T., Arenzana-Seisdedos F., Ikeda K., Matsui T., Tanimoto M., Katayama Y. Rapid hematopoietic progenitor mobilization by sulfated colominic acid. Biochem Biophys Res Commun. 2007; 355 (4): 970–5. doi: 10.1016/j.bbrc.2007.02.069.Anisimova N. Y., Ustyuzhanina N. E., Bilan M. I., Donenko F. V., Ushakova N. A., Usov A. I., Kiselevskiy M. V., Nifantiev N. E. Infl uence of modified fucoidan and related sulfated oligosaccharides on hematopoiesis in cyclophosphamide-induced mice. Mar Drugs. 2018; 16 (9): 333. doi: 10.3390/md16090333.Anisimova N. Y., Ustyuzhanina N. E., Bilan M. I., Donenko F. V., Ushakova N. A., Usov A. I., Kiselevskiy M. V., Nifantiev N. E. Infl uence of modified fucoidan and related sulfated oligosaccharides on hematopoiesis in cyclophosphamide-induced mice. Mar Drugs. 2018; 16 (9): 333. doi: 10.3390/md16090333.Yan H., Baldridge M. T., King K. Y. Hematopoiesis and the bacterial microbiome. Blood. 2018; 132 (6): 559–64. doi: 10.1182/blood-2018-02-832519.Yan H., Baldridge M. T., King K. Y. Hematopoiesis and the bacterial microbiome. Blood. 2018; 132 (6): 559–64. doi: 10.1182/blood-2018-02-832519.Iwamura C., Bouladoux N., Belkaid Y., Sher A., Jankovic D. Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis. Blood. 2017; 129 (2): 171–6. doi: 10.1182/blood-2016-06-723742.Iwamura C., Bouladoux N., Belkaid Y., Sher A., Jankovic D. Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis. Blood. 2017; 129 (2): 171–6. doi: 10.1182/blood-2016-06-723742.Staffas A., Burgos da Silva M., Slingerland A. E., Lazrak A., Bare C. J., Holman C. D., Docampo M. D., Shono Y., Durham B., Pickard A. J., Cross J. R., Stein-Thoeringer C., Velardi E., Tsai J. J., Jahn L., Jay H., Lieberman S., Smith O. M., Pamer E. G., Peled J. U., Cohen D. E., Jenq R. R., van den Brink M. R. M. Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone marrow transplantation in mice. Cell Host Microbe. 2018; 23 (4): 447–57.e4. doi: 10.1016/j.chom.2018.03.002.Staffas A., Burgos da Silva M., Slingerland A. E., Lazrak A., Bare C. J., Holman C. D., Docampo M. D., Shono Y., Durham B., Pickard A. J., Cross J. R., Stein-Thoeringer C., Velardi E., Tsai J. J., Jahn L., Jay H., Lieberman S., Smith O. M., Pamer E. G., Peled J. U., Cohen D. E., Jenq R. R., van den Brink M. R. M. Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone marrow transplantation in mice. Cell Host Microbe. 2018; 23 (4): 447–57.e4. doi: 10.1016/j.chom.2018.03.002.Peled J. U., Devlin S. M., Staffas A., Lumish M., Khanin R., Littmann E. R., Ling L., Kosuri S., Maloy M., Slingerland J. B., Ahr K. F., Porosnicu Rodriguez K. A., Shono Y., Slingerland A. E., Docampo M. D., Sung A. D., Weber D, Alousi A. M., Gyurkocza B., Ponce D. M., Barker J. N., Perales M. A., Giralt S. A., Taur Y., Pamer E. G., Jenq R. R., van den Brink M. R. M. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017; 35 (15): 1650–9. doi: 10.1200/JCO.2016.70.3348.Peled J. U., Devlin S. M., Staffas A., Lumish M., Khanin R., Littmann E. R., Ling L., Kosuri S., Maloy M., Slingerland J. B., Ahr K. F., Porosnicu Rodriguez K. A., Shono Y., Slingerland A. E., Docampo M. D., Sung A. D., Weber D, Alousi A. M., Gyurkocza B., Ponce D. M., Barker J. N., Perales M. A., Giralt S. A., Taur Y., Pamer E. G., Jenq R. R., van den Brink M. R. M. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017; 35 (15): 1650–9. doi: 10.1200/JCO.2016.70.3348.Shang Q., Shan X., Cai C. Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance of Lactobacillus and Ruminococcaceae. Food Funct. 2016; 7 (7): 3224–32. doi: 10.1039/c6fo00309e.Shang Q., Shan X., Cai C. Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance of Lactobacillus and Ruminococcaceae. Food Funct. 2016; 7 (7): 3224–32. doi: 10.1039/c6fo00309e.Cumashi A., Ushakova N. A., Preobrazhenskaya M. E., D'Incecco A., Piccoli A., Totani L., Tinari N., Morozevich G. E., Berman A. E., Bilan M. I., Usov A. I., Ustyuzhanina N. E., Grachev A. A., Sanderson C. J., Kelly M., Rabinovich G. A., Iacobelli S., Nifantiev N. E. Consorzio Interuniversitario Nazionale per la Bio-Oncologia, Italy. Comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 2007; 17 (5): 541–52. doi: 10.1093/glycob/cwm014.Cumashi A., Ushakova N. A., Preobrazhenskaya M. E., D'Incecco A., Piccoli A., Totani L., Tinari N., Morozevich G. E., Berman A. E., Bilan M. I., Usov A. I., Ustyuzhanina N. E., Grachev A. A., Sanderson C. J., Kelly M., Rabinovich G. A., Iacobelli S., Nifantiev N. E. Consorzio Interuniversitario Nazionale per la Bio-Oncologia, Italy. Comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 2007; 17 (5): 541–52. doi: 10.1093/glycob/cwm014.Pomin V. H. Holothurian fucosylated chondroitin sulfates. Mar Drugs. 2014; 12 (1): 232–54. doi: 10.3390/md12010232.Pomin V. H. Holothurian fucosylated chondroitin sulfates. Mar Drugs. 2014; 12 (1): 232–54. doi: 10.3390/md12010232.Ustyuzhanina N. E., Ushakova N. A., Zyuzina K. A., Bilan M. I., Elizarova A. L., Somonova O. V., Madzhuga A. V., Krylov V. B., Preobrazhenskaya M. E., Usov A. I., Kiselevskiy M. V., Nifantiev N. E. Influence of fucoidans on hemostatic system. Mar Drugs. 2013; 11 (7): 2444–58. doi: 10.3390/md11072444.Ustyuzhanina N. E., Ushakova N. A., Zyuzina K. A., Bilan M. I., Elizarova A. L., Somonova O. V., Madzhuga A. V., Krylov V. B., Preobrazhenskaya M. E., Usov A. I., Kiselevskiy M. V., Nifantiev N. E. Influence of fucoidans on hemostatic system. Mar Drugs. 2013; 11 (7): 2444–58. doi: 10.3390/md11072444.

The authors declare that there are no conflicts of interest present.